Brigitte Van Eyll

1.5k total citations
13 papers, 354 citations indexed

About

Brigitte Van Eyll is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Brigitte Van Eyll has authored 13 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Brigitte Van Eyll's work include Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (7 papers) and Diabetes Treatment and Management (3 papers). Brigitte Van Eyll is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (7 papers) and Diabetes Treatment and Management (3 papers). Brigitte Van Eyll collaborates with scholars based in Brazil, Germany and France. Brigitte Van Eyll's co-authors include Rüdiger Göke, Andreas Wilmen, Burkhard Göke, Paulo M. Hoff, Brigitte Lankat–Buttgereit, Burkhard Göke, G. Kurteva, Laura A. Pike, Anitra Fielding and Tamás Pintér and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and FEBS Letters.

In The Last Decade

Brigitte Van Eyll

13 papers receiving 345 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brigitte Van Eyll Brazil 9 209 124 90 90 63 13 354
Anton Stangelberger United States 10 112 0.5× 101 0.8× 156 1.7× 100 1.1× 21 0.3× 12 343
Fatih Özdener Türkiye 9 119 0.6× 91 0.7× 59 0.7× 8 0.1× 48 0.8× 37 370
Vasili Egnatashvili United States 7 118 0.6× 105 0.8× 84 0.9× 13 0.1× 103 1.6× 8 361
Devrim Çabuk Türkiye 9 79 0.4× 49 0.4× 45 0.5× 19 0.2× 16 0.3× 37 191
M.J. Lechuga Italy 10 64 0.3× 150 1.2× 130 1.4× 98 1.1× 19 0.3× 18 351
Chunguang Guo China 12 170 0.8× 141 1.1× 58 0.6× 10 0.1× 60 1.0× 25 345
Songfeng Zhao China 8 49 0.2× 100 0.8× 53 0.6× 28 0.3× 22 0.3× 18 255
Liguang Wang China 10 85 0.4× 78 0.6× 76 0.8× 31 0.3× 56 0.9× 15 303
Tomoaki Urakawa Japan 9 194 0.9× 98 0.8× 56 0.6× 7 0.1× 124 2.0× 55 390
Benjamin Levinson United States 11 125 0.6× 133 1.1× 103 1.1× 6 0.1× 44 0.7× 26 344

Countries citing papers authored by Brigitte Van Eyll

Since Specialization
Citations

This map shows the geographic impact of Brigitte Van Eyll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Van Eyll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Van Eyll more than expected).

Fields of papers citing papers by Brigitte Van Eyll

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Van Eyll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Van Eyll. The network helps show where Brigitte Van Eyll may publish in the future.

Co-authorship network of co-authors of Brigitte Van Eyll

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitte Van Eyll. A scholar is included among the top collaborators of Brigitte Van Eyll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitte Van Eyll. Brigitte Van Eyll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Hoff, Paulo M., Carlos H. Barrios, Auro del Giglio, et al.. (2014). Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial. Journal of Clinical Oncology. 32(10). 1006–1011. 39 indexed citations
2.
Hoff, Paulo M., Andreas Hochhaus, Bernhard C. Pestalozzi, et al.. (2012). Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology. 30(29). 3596–3603. 112 indexed citations
3.
Hoff, Paulo M., Carlos H. Barrios, Auro del Giglio, et al.. (2012). A randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: The LARCID trial.. Journal of Clinical Oncology. 30(4_suppl). 549–549. 3 indexed citations
4.
5.
6.
7.
Segalla, J. G. M., et al.. (2008). Evaluation of Quality of Life in Patients with Metastatic Colorectal Cancer Treated with Capecitabine. Clinical Colorectal Cancer. 7(2). 126–133. 10 indexed citations
8.
Segalla, J. G. M., et al.. (2005). Evaluation of quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC) treated with capecitabine (X). Journal of Clinical Oncology. 23(16_suppl). 8090–8090. 3 indexed citations
9.
Beato, Carlos, et al.. (2004). Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 22(14_suppl). 8119–8119. 4 indexed citations
10.
Beato, Carlos, et al.. (2004). Effects of capecitabine (X) on quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 22(14_suppl). 8119–8119. 1 indexed citations
11.
Wilmen, Andreas, Brigitte Van Eyll, Burkhard Göke, & Rüdiger Göke. (1997). Five Out of Six Tryptophan Residues in the N -Terminal Extracellular Domain of the Rat GLP-1 Receptor Are Essential for its Ability to Bind GLP-1. Peptides. 18(2). 301–305. 42 indexed citations
12.
Eyll, Brigitte Van, Burkhard Göke, Andreas Wilmen, & Rüdiger Göke. (1996). Exchange of W39 by A within the N-terminal extracellular domain of the GLP-1 receptor results in a loss of receptor function. Peptides. 17(4). 565–570. 23 indexed citations
13.
Eyll, Brigitte Van, et al.. (1994). Signal transduction of the GLP‐1‐receptor cloned from a human insulinoma. FEBS Letters. 348(1). 7–13. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anton Stangelberger Breakdown of academic impact, for papers by Fatih Özdener Breakdown of academic impact, for papers by Vasili Egnatashvili Breakdown of academic impact, for papers by Devrim Çabuk Breakdown of academic impact, for papers by M.J. Lechuga Breakdown of academic impact, for papers by Chunguang Guo Breakdown of academic impact, for papers by Songfeng Zhao Breakdown of academic impact, for papers by Liguang Wang Breakdown of academic impact, for papers by Tomoaki Urakawa Breakdown of academic impact, for papers by Benjamin Levinson
Rankless by CCL
2026